SAR-20293

N/A

Report date: 2025/06/11 10:24:48
NME

Base Information

Drug NameSAR-20293
Drug Alias Namedual aurora/Flt 3 inhibitors (Sareum/ HMUBEC)FLT3+Aurora kinases inhibitor (Sareum)dual aurora/Flt 3 inhibitors (Sareum)SAR-1SAR-2 +[8] 
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsAnticancer protein kinase inhibitorsSerine/threonine-protein kinase Aurora inhibitors
TargetsSerine/threonine-protein kinase AuroraTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSareum Holdings plc
China Registration ClassN/A

Develop Information

Active CompaniesSareum Holdings plc
Inactive CompaniesHebei Medical University
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A